10:20 AM EDT, 10/24/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that updated data from a phase 1 study of zocilurtatug pelitecan, or zoci, showed a high response rate across all dose levels in heavily pre-treated patients with extensive-stage small cell lung cancer.

As a second-line treatment, zoci, formerly known as ZL-1310, demonstrated a 68% overall response rate in patients receiving 1.6 mg/kg, the company said.

Responses were also durable, with the estimated median duration of response at 6.1 months and median progression-free survival at 5.4 months across all doses, Zai Lab ( ZLAB ) said.

The investigational drug also continues to show a well-tolerated safety profile, especially at the 1.2 or 1.6 mg/kg doses, the company said.

The company added that it has opened for patient enrollment the phase 3 registrational study of zoci, designed to further assess its safety and efficacy compared with investigator's choice single agent therapy in patients with relapsed small cell lung cancer.

Zai Lab ( ZLAB ) shares were down nearly 2% in recent trading Friday.

Price: 27.49, Change: -0.53, Percent Change: -1.89